Tevogen Announces Reverse Stock Split
Rhea-AI Summary
Tevogen (Nasdaq: TVGN) announced a 50-for-1 reverse stock split to regain compliance with Nasdaq's $1.00 minimum bid requirement. The split is expected to be effective at 12:01 a.m. on March 6, 2026, with shares trading on a split-adjusted basis under the same symbol and a new CUSIP.
No fractional shares will be issued; holders entitled to fractions will receive cash in lieu. Equity awards, warrants, incentive plan shares and preferred conversions will be proportionally adjusted. The company said the split will not affect underlying operations or total stockholders' equity.
Positive
- 50-for-1 reverse split effective March 6, 2026
- Aims to regain Nasdaq $1.00 minimum bid compliance
- Equity awards and warrants will be proportionally adjusted
- Company stated no impact on business operations or total equity
Negative
- Holders entitled to fractional shares will receive cash in lieu
- Insiders beneficially own >70% of common stock, concentrating ownership
- Reverse split may reduce public float given current share structure
News Market Reaction – TVGN
On the day this news was published, TVGN declined 24.83%, reflecting a significant negative market reaction. Argus tracked a trough of -25.2% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $16M from the company's valuation, bringing the market cap to $50M at that time. Trading volume was elevated at 2.1x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TVGN’s setup around a 50-for-1 reverse split appears stock-specific. Key biotech peers like KYTX (-3.14%), CRBU (-2.22%), IPHA (-2.47%) and NTHI (-5.56%) were down, while VTYX was roughly flat at 0.07%. Momentum scanners only flagged SLS at +4.14%, reinforcing that this is not a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 27 | CRO acquisition LOI | Positive | -8.7% | Non-binding LOI to evaluate acquiring a global Contract Research Organization. |
| Feb 26 | Digital platform LOI | Positive | -8.7% | LOI to evaluate acquiring majority interest in Sciometrix and Clinicus platform. |
| Feb 26 | Digital platform LOI | Positive | +0.1% | Details on potential Sciometrix acquisition to build revenue-generating enterprise. |
| Jan 30 | Special dividend review | Positive | +1.7% | Board to evaluate potential one-time special cash dividend tied to milestones. |
| Jan 29 | Incentive plan update | Positive | -5.9% | Long-term stock incentives aligned with revenue and milestone-based objectives. |
Recent strategically positive announcements have often been met with selling, with several acquisition-related updates followed by ~9% declines.
Over recent months, Tevogen focused on strategic expansion and capital structure. On Jan 29, it tied incentives to revenue and long-term milestones. On Jan 30, the Board began evaluating a potential special cash dividend. In late February, multiple LOIs for CRO and digital platform acquisitions were announced, but shares fell up to 8.71%. An earlier 8-K disclosed Nasdaq’s $1.00 bid-price deficiency, and February proxy materials detailed the reverse split range, directly connecting this announcement to that compliance plan.
Market Pulse Summary
The stock dropped -24.8% in the session following this news. A negative reaction despite the compliance-focused 50-for-1 reverse split would fit a pattern where shares fell after prior seemingly constructive news, including ~8.71% declines on recent acquisition LOIs. The stock had been trading at $0.2477, far below the $1.00 Nasdaq threshold and 83.6% under its $1.51 52-week high. Investors would need to consider whether concerns about dilution, capital needs, or reverse-split optics outweighed the listing-compliance objective.
Key Terms
reverse stock split financial
nasdaq global market regulatory
cusip technical
equity awards financial
equity incentive plan financial
preferred stock financial
AI-generated analysis. Not financial advice.
WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of its common stock at a ratio of 50 for 1. Stockholders previously approved the reverse stock split on February 19, 2026, and provided the Board with discretion to determine the final reverse stock split ratio.
The reverse stock split is being conducted to regain compliance with the
On the Effective Date, every 50 shares of the Company’s common stock issued and outstanding will be automatically converted into one share. No fractional shares will be issued in connection with the reverse stock split. Holders of common stock who would otherwise receive a fractional share pursuant to the reverse stock split will receive cash in lieu of the fractional share. The shares of common stock underlying the Company’s outstanding equity awards and warrants, the number of shares available for issuance under the Company’s equity incentive plan, and the number of shares issuable upon conversion of the Company’s outstanding preferred stock will also be adjusted accordingly.
The reverse stock split will be applicable to all holders of our common stock uniformly and will not affect any stockholder’s percentage of ownership interest in the Company, except for any changes resulting from the treatment of fractional shares. This includes percentage of ownership for Tevogen directors and executive officers who currently beneficially own more than
The following chart shows percentage ownership of the Company’s common stock based on 201,417,282 shares issued and outstanding as of January 14, 2026.
Additional information regarding the reverse stock split is available in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on January 26, 2026.
About Tevogen
Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.
Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.
Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.
Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: compliance with the minimum bid price requirement and other applicable Nasdaq continued listing standards and the effect of the reverse stock split; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the Company’s control that may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2d041330-3295-448c-b322-c461b0f4c76b
FAQ
What reverse stock split did Tevogen (TVGN) approve and when is it effective?
Why is Tevogen (TVGN) implementing the 50-for-1 reverse split?
How will fractional shares be handled after Tevogen's (TVGN) reverse split?
Will Tevogen's (TVGN) reverse split change total stockholders' equity or operations?
How does the reverse split affect insider ownership in Tevogen (TVGN)?
